
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.65 | -18.1058495822 | 3.59 | 3.75 | 2.8 | 522149 | 3.12444117 | CS |
4 | -1.3 | -30.6603773585 | 4.24 | 4.43 | 2.8 | 470720 | 3.60838601 | CS |
12 | -4.01 | -57.6978417266 | 6.95 | 7.06 | 2.8 | 798646 | 4.32122644 | CS |
26 | -4.88 | -62.4040920716 | 7.82 | 13.07 | 2.8 | 777289 | 6.95044329 | CS |
52 | -13.07 | -81.6364772017 | 16.01 | 19.3549 | 2.8 | 971101 | 8.41684215 | CS |
156 | -3.83 | -56.5731166913 | 6.77 | 43.69 | 2.8 | 667907 | 14.32552366 | CS |
260 | -17.06 | -85.3 | 20 | 43.69 | 2.8 | 549835 | 14.19481092 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.